Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	63.7	66.38	65.18	73.8	96.67	65.63
Revenue Growth (YoY)	-0.38%	1.84%	-11.68%	-23.66%	47.29%	137.52%
Cost of Revenue	20.66	20.55	16.13	21.57	46.39	36.43
Gross Profit	43.03	45.83	49.05	52.23	50.28	29.2
Selling, General & Admin	37.75	38.29	42.04	49.77	69.88	55.81
Research & Development	0.9	1.33	2.77	3.98	12.66	5.62
Amortization of Goodwill & Intangibles	3.21	3.68	3.68	3.69	5.84	6.01
Operating Expenses	41.85	43.29	48.49	57.44	88.39	67.44
Operating Income	1.18	2.54	0.57	-5.21	-38.1	-38.24
Interest Expense	-3.23	-3.7	-5.06	-5.15	-0.01	-0.01
Other Non Operating Income (Expenses)	-1.65	-2.22	-3.13	5.22	0.86	-2.04
EBT Excluding Unusual Items	-3.7	-3.38	-7.63	-5.14	-37.26	-40.29
Merger & Restructuring Charges	-1.32	-2.1	-2.16	-	-	-7.81
Impairment of Goodwill	-	-	-	-	-65.8	-
Asset Writedown	-8.26	-8.26	-	-2.73	-7.66	-12.83
Other Unusual Items	-	-	-0.59	0.58	1.82	2.89
Pretax Income	-13.28	-13.75	-10.38	-7.29	-108.89	-58.03
Income Tax Expense	0.03	0.44	2.14	0.26	-0.11	0.26
Earnings From Continuing Operations	-13.31	-14.18	-12.52	-7.55	-108.78	-58.29
Earnings From Discontinued Operations	0.24	0.62	-3.32	-9.5	-	-
Net Income	-13.07	-13.56	-15.84	-17.05	-108.78	-58.29
Net Income to Common	-13.07	-13.56	-15.84	-17.05	-108.78	-58.29
Shares Outstanding (Basic)	7	6	6	3	1	1
Shares Outstanding (Diluted)	7	6	6	3	1	1
Shares Change (YoY)	25.31%	13.40%	65.81%	127.22%	75.54%	270.57%
EPS (Basic)	-1.84	-2.16	-2.86	-5.11	-74.01	-69.61
EPS (Diluted)	-1.92	-2.16	-2.86	-5.11	-74.01	-69.61
Free Cash Flow	-1.46	-2.17	-1.72	-5.13	-28.82	-28.31
Free Cash Flow Per Share	-0.20	-0.34	-0.31	-1.54	-19.61	-33.80
Gross Margin	67.56%	69.04%	75.26%	70.77%	52.02%	44.49%
Operating Margin	1.85%	3.82%	0.87%	-7.05%	-39.42%	-58.26%
Profit Margin	-20.52%	-20.43%	-24.31%	-23.11%	-112.53%	-88.81%
Free Cash Flow Margin	-2.29%	-3.26%	-2.63%	-6.95%	-29.82%	-43.13%
EBITDA	6.03	7.91	7.29	2.49	-27.96	-29.04
EBITDA Margin	9.46%	11.92%	11.18%	3.38%	-28.92%	-44.25%
D&A For EBITDA	4.85	5.38	6.73	7.7	10.15	9.2
EBIT	1.18	2.54	0.57	-5.21	-38.1	-38.24
EBIT Margin	1.85%	3.82%	0.87%	-7.05%	-39.42%	-58.26%
Advertising Expenses	-	-	-	-	13.6	15.2

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q